Publications by authors named "V Xyla"
Article Synopsis
- Chronic hepatitis C virus (HCV) infection often leads to peripheral neuropathy (PN), especially in patients with mixed cryoglobulinemia, but the prevalence of PN without MCG is less known.
- A study was conducted on 40 HCV-infected individuals, some co-infected with HIV, to assess the prevalence and reversibility of HCV-related neuropathy, using skin biopsies and electroneurography (ENG) for evaluation.
- Results indicated that PN was present in 22.5% of HCV mono-infected and 44% of co-infected patients, with nerve density improving significantly one year after successful HCV treatment.
Background: Natalizumab is administered for the treatment of relapsing-remitting multiple sclerosis (RR-MS) with high disease activity.Natalizumab therapy has been associated with adverse effects, such as progressive multifocal leukoencephalopathy, liver damage, nasopharyngitis, urinary tract infection, urticaria, cephalgia, dizziness, fatigue, nausea, fever, rigidity, anxiety and gastroenteritis.
Objective: To describe a case of a woman with RR-MS who developed recurrent vaginitis on natalizumab administration.
Mediterranean Kaposi's sarcoma (MKS), HIV-related KS (HIV-KS) and immunosuppression-associated KS (IS-KS), caused by human herpes virus 8 (HHV-8), share similar histological features. The aim of this study was to investigate differences in epidermal nerve fibers (ENFs) between the three KS types and controls. Skin biopsies from 23 HIV-KS, 16 MKS, 28 IS-KS patients and 18 controls, age-gender matched, were immunostained with PGP 9.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the effectiveness of FDG-PET scans in detecting recurrent liver metastases after radiofrequency ablation (RFA).
- It analyzes data from nine articles, revealing a sensitivity of 0.73 and specificity of 0.85, indicating reasonably reliable detection rates.
- The findings support using PET/CT scans as a valuable method for monitoring patients after RFA, particularly for those with surgical RFA and colorectal metastases.
Carboplatin is a chemotherapeutic agent approved in the first-line setting of numerous malignancies. Hypersensitivity to carboplatin has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment. The aim of this study was to determine the usefulness of skin tests in ruling out cross-reaction to cisplatin to continue platinum-based chemotherapy in patients who are responsive to these agents.
View Article and Find Full Text PDF